<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02251626</url>
  </required_header>
  <id_info>
    <org_study_id>2013P001111</org_study_id>
    <nct_id>NCT02251626</nct_id>
  </id_info>
  <brief_title>Assessing Bioavailability of CoQ10 Supplementation in Burn Patients</brief_title>
  <acronym>CoQ10</acronym>
  <official_title>Assessing Bioavailability and Effects of Ubiquinol Supplementation on Biomarkers of Mitochondrial Function/Integrity, Metabolic Dysfunction, and Circulating Alarmins in Burn Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kaneka Medical America LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test the hypotheses that plasma and intracellular coenzyme Q10 levels will decline after&#xD;
      burn injury and that ubiquinol supplementation will increase plasma and intracellular&#xD;
      coenzyme Q10 levels in burn patients.&#xD;
&#xD;
      To test the hypothesis that ubiquinol supplementation ameliorates mitochondrial&#xD;
      dysfunction/disintegrity and metabolic derangements, and decreases circulating alarmins&#xD;
      (a.k.a. endogenous DAMPs) in burn patients as compared with placebo.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Based on previous clinical studies and our preliminary preclinical data, we want to test the&#xD;
      hypotheses that plasma and intracellular coenzyme Q10 levels are decreased after burn injury&#xD;
      and that coenzyme Q10 (ubiquinol) supplementation reverses or ameliorates insulin resistance,&#xD;
      metabolic derangements, mitochondrial dysfunction, and increased circulating DAMPs in burn&#xD;
      patients. The aforementioned previous studies and preliminary data warrant a small-scale&#xD;
      clinical study to evaluate coenzyme Q10 status, and bioavailability and efficacy of coenzyme&#xD;
      Q10 (ubiquinol) supplementation in burn patients. Coenzyme Q10 (ubiquinol) supplementation&#xD;
      could represent a novel, safe and low-cost strategy to improve the clinical outcome of burn&#xD;
      patients. We are conducting a randomized, double-blind, placebo-controlled intervention study&#xD;
      with anticipated enrollment of 50 subjects. Adult burn patients with 5% or greater of total&#xD;
      body surface area (TBSA) burn at the Massachusetts General Hospital (MGH) Burn Center will be&#xD;
      approached to consider study participation. All enrolled patients will be randomized to&#xD;
      receive coenzyme Q10 (ubiquinol) supplementation or placebo. Blood samples will be used for&#xD;
      evaluation of coenzyme Q10 concentration, mitochondrial DNA copy number, non-mitochondrial&#xD;
      DAMPs (e.g., cell-free total DNA), and defective neutrophil migration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coenzyme Q10 Content in Peripheral Blood Mononuclear Cells</measure>
    <time_frame>up to four weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Coenzyme Q10 Concentration</measure>
    <time_frame>up to four weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Mitochondrial DNA Concentration</measure>
    <time_frame>up to four weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma cytokine concentrations</measure>
    <time_frame>up to four weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Burn Injury</condition>
  <arm_group>
    <arm_group_label>Coenzyme Q10 (ubiquinol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coenzyme Q10 (ubiquinol) group will be given 1,800 mg coenzyme Q10 (ubiquinol) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for CoQ10 (ubiquinol)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group will be given placebo only</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>coenzyme Q10</intervention_name>
    <description>It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.</description>
    <arm_group_label>Coenzyme Q10 (ubiquinol)</arm_group_label>
    <other_name>Ubiquinol supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.</description>
    <arm_group_label>Placebo for CoQ10 (ubiquinol)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ages eligible for study: 18 years and older, and below 85 yeas old&#xD;
&#xD;
          -  Burn patients with 5% or greater of total body surface area burn&#xD;
&#xD;
          -  Nutrition support: routine oral and/or enteral nutrition&#xD;
&#xD;
          -  Enrolled within one week after burn injury&#xD;
&#xD;
          -  Patient or guardian who is capable of giving full informed consent.&#xD;
&#xD;
          -  Anticipated stay in the MGH Burn Unit: 5 days or more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 5% TBSA burn&#xD;
&#xD;
          -  Patients required full parenteral nutrition without oral or enteral nutrition support.&#xD;
&#xD;
          -  Patients with liver disease (bilirubin greater than 3)&#xD;
&#xD;
          -  Patients with thyroid disorders (thyroid disease which currently require treatment)&#xD;
&#xD;
          -  Patients with malignancy under treatment&#xD;
&#xD;
          -  Patients with mental illness who have impaired decision-making capacity (Mental&#xD;
             illness defined by the presence of psychotropic medications and/or the diagnosis of&#xD;
             psychiatric illness at the time of admission.) Patients with mental illness can be&#xD;
             included unless it is determined by the psychiatrist covering the burn unit that they&#xD;
             are unable to consent for themselves for other aspects of their care and treatment.)&#xD;
&#xD;
          -  Patients with HIV*&#xD;
&#xD;
          -  Pregnancy (as determined by routine admission labs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masao Kaneki, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Masao Kaneki, MD, PhD</last_name>
    <phone>617-726-8122</phone>
    <email>mkaneki@helix.mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jeremy Goverman, MD</last_name>
    <phone>617-726-3712</phone>
    <email>JGOVERMAN@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masao Kaneki, MD, PhD</last_name>
      <phone>617-726-8122</phone>
      <email>mkaneki@helix.mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jeremy Goverman, MD</last_name>
      <phone>617-726-3712</phone>
      <email>JGOVERMAN@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Masao Kaneki, MD. PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>September 20, 2014</study_first_submitted>
  <study_first_submitted_qc>September 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2014</study_first_posted>
  <last_update_submitted>September 13, 2016</last_update_submitted>
  <last_update_submitted_qc>September 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Masao Kaneki</investigator_full_name>
    <investigator_title>Associate Professor/Associate Biochemist, Department of Anesthesia,Critical Care and Pain Medicine</investigator_title>
  </responsible_party>
  <keyword>MGH</keyword>
  <keyword>Burn patient</keyword>
  <keyword>Adult</keyword>
  <keyword>CoQ10</keyword>
  <keyword>Ubiquinol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

